The Effect of Hepatic Impairment on the Pharmacokinetics of Asunaprevir, an HCV NS3 Protease Inhibitor
Antiviral Therapy2014Vol. 20(1), pp. 29–37
Citations Over TimeTop 10% of 2014 papers
Timothy Eley, Bing He, Ih Chang, Elizabeth Colston, Michael Child, William Bedford, Hamza Kandoussi, C Pasquinelli, Thomas Marbury, Richard Bertz
Abstract
Mild hepatic impairment does not meaningfully affect the pharmacokinetic profile of asunaprevir. The dosing of asunaprevir in patients with moderate-to-severe hepatic impairment is not recommended. Clinicaltrials.gov identifier NCT01019070.
Related Papers
- → Intervention of curcumin on oral pharmacokinetics of daclatasvir in rat: A possible risk for long‐term use(2018)22 cited
- → Vehicle development, pharmacokinetics and toxicity of the anti-invasive agent 4-fluoro-3’,4’,5’-trimethoxychalcone in rodents(2018)9 cited
- → Assessment of Presystemic Factors on the Oral Bioavailability of Rifampicin Following Multiple Dosing(1998)17 cited
- → Pharmacokinetics of oral pridinol: Results of a randomized, crossover bioequivalence trial in healthy subjects(2021)5 cited
- → P4–268: Pharmacokinetics and pharmacodynamics of CHF5022 and CHF5074, two new β–amyloid1–42 lowering agents, after multiple doses in TG2576 transgenic mice(2006)